Request appointment
1 Gustave L Levy PlNew York, NY 10029
Fax+1 212-731-5210
Overview of Dr. Friedlander
Dr. Philip Friedlander is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, and Valley Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 27 years. Dr. Friedlander accepts several types of health insurance, listed below. He is one of 187 doctors at The Mount Sinai Hospital and one of 120 doctors at Mount Sinai Beth Israel who specialize in Oncology. He has more than 40 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
FL State Medical License 2020 - Present
NJ State Medical License 2017 - 2027
NY State Medical License 2000 - 2027
MA State Medical License 2005 - 2012
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
Clinical Trials
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
- The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Publications & Presentations
PubMed
- 2 citationsThe telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.Paul Lorigan, Theresa Michelle Medina, Marta Nyakas, Annemie Rutten, Lynn G Feun
European Journal of Cancer. 2026-01-17 - 5 citationsPhase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, Glenn J Hanna, Douglas E Laux
Journal for Immunotherapy of Cancer. 2025-07-25 - 15 citationsPGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.Mansi Saxena, Thomas U Marron, Julia Kodysh, John P Finnigan Jr, Sayali Onkar
Cancer Discovery. 2025-05-02
Press Mentions
Experts Agree Sun Exposure Is a Cancer RiskSeptember 7th, 2022- Immune-Boosting Components Double the Effectiveness of Melanoma Vaccine Candidate in Phase II TrialNovember 17th, 2020
'Truly Amazing': Huge Change in Melanoma PrognosisOctober 26th, 2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS California PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
Health Net California Large Group PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
